TCBP Profile
TC Biopharm (Holdings) Plc, headquartered in Motherwell, United Kingdom, operates as a dynamic clinical-stage biopharmaceutical firm specializing in the development of innovative immunotherapy products. Founded in 2013, the company focuses on leveraging its proprietary allogeneic gamma delta T cell platform to advance transformative therapies for various medical conditions.
At the forefront of TC Biopharm's product pipeline is OmnImmune, an unmodified cell therapy designed to target acute myeloid leukemia (AML). This pioneering treatment underscores the company's commitment to addressing critical unmet needs in oncology by harnessing the power of the immune system to combat cancer.
In response to global health challenges, TC Biopharm is also developing ImmuniStim, an unmodified cell therapy aimed at addressing COVID-19. This initiative highlights the company's agility and dedication to applying its innovative technologies to combat emerging infectious diseases and contribute to global public health.
With a robust portfolio of cutting-edge therapies and a strong emphasis on research and development, TC Biopharm (Holdings) Plc continues to expand its footprint in the biopharmaceutical sector. Through strategic partnerships, clinical trials, and regulatory advancements, the company strives to deliver impactful treatments that improve patient outcomes and redefine standards of care worldwide.
|
